The company said revenue for fiscal 2024 rose $31.8 billion (12.1%) from the prior year, and gross profit increased $950.5 million (10.6%). It cited growth in sales of GLP-1-class products at U.S. Healthcare Solutions among the drivers of the revenue increase.

10-KAnnual reportFiled Nov 26, 2024Period of report Sep 30, 2024Summary published (UTC) Oct 24, 2026

Key points

AI summary

The company said revenue for fiscal 2024 rose $31.8 billion (12.1%) from the prior year, and gross profit increased $950.5 million (10.6%). It cited growth in sales of GLP-1-class products at U.S. Healthcare Solutions among the drivers of the revenue increase.
Cencora said it recorded a goodwill impairment of $418.0 million related to PharmaLex in fiscal 2024, and total operating expenses rose $1,116.0 million (16.9%). The company cited the impairment, which is largely not tax-deductible, as the main factor behind its effective tax rate of 24.2% (19.8% in the prior year).
The company said it generated $3.5 billion in cash from operating activities in fiscal 2024, and net cash provided by operating activities fell $426.6 million from the prior year. It cited the timing of cash receipts and payments in working capital accounts as the main factor.
The company said that on November 5, 2024, it entered into an agreement to acquire Retina Consultants of America (RCA) for cash based on an enterprise value of approximately $4.6 billion. It said its expected cash outlay at closing would be approximately $4.3 billion, and it has obtained $3.3 billion in bridge financing commitments.

Key figures

Fiscal year ended September 30, 2024

Revenue: $294.0B
Operating income: $2.2B
Net income: $1.5B
EPS: $7.53
Gross profit: $9.9B
Operating cash flow: $3.5B

From the XBRL financial data filed with the SEC · not processed by AI.

Summary

AI-written

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

Annual Revenue and Gross Profit Growth

The company said revenue for fiscal 2024 rose $31.8 billion (12.1%) from the prior year, and gross profit increased $950.5 million (10.6%). It cited growth in sales of GLP-1-class products at U.S. Healthcare Solutions among the drivers of the revenue increase.

Source · Based on the MD&A text of the filing

PharmaLex Goodwill Impairment

Cencora said it recorded a goodwill impairment of $418.0 million related to PharmaLex in fiscal 2024, and total operating expenses rose $1,116.0 million (16.9%). The company cited the impairment, which is largely not tax-deductible, as the main factor behind its effective tax rate of 24.2% (19.8% in the prior year).

Source · Based on the MD&A text of the filing

Operating Cash Flow

The company said it generated $3.5 billion in cash from operating activities in fiscal 2024, and net cash provided by operating activities fell $426.6 million from the prior year. It cited the timing of cash receipts and payments in working capital accounts as the main factor.

Source · Based on the MD&A text of the filing

Retina Consultants of America Acquisition Agreement

The company said that on November 5, 2024, it entered into an agreement to acquire Retina Consultants of America (RCA) for cash based on an enterprise value of approximately $4.6 billion. It said its expected cash outlay at closing would be approximately $4.3 billion, and it has obtained $3.3 billion in bridge financing commitments.

Source · Based on the MD&A text of the filing

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.